期刊
FRONTIERS IN CARDIOVASCULAR MEDICINE
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2023.1220017
关键词
eicosapentaenoic acid; cardiovascular disease; cost effectiveness; icosapent ethyl; eligibility
This review summarizes the eligibility and cost effectiveness studies of IPE conducted to date. Sixteen studies with 2,068,111 patients in primary or secondary prevention settings worldwide were included. The proportion of patients eligible for IPE ranged from 15% to 45%, depending on the selection criteria and population studied. Overall, eight cost-effectiveness studies from the US, Canada, Germany, Israel, and Australia indicated that IPE is particularly cost effective in patients with established CVD.
Icosapent ethyl (IPE) is a purified eicosapentaenoic acid-only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and additional risk factors in the pivotal REDUCE-IT trial. Since the publication of REDUCE-IT, there has been global interest in determining IPE eligibility in different patient populations, the proportion of patients who may benefit from IPE, and cost effectiveness of IPE in primary and secondary prevention settings. The aim of this review is to summarize information from eligibility and cost effectiveness studies of IPE to date. A total of sixteen studies were reviewed, involving 2,068,111 patients in the primary or secondary prevention settings worldwide. Up to forty-five percent of patients were eligible for IPE, depending on the selection criteria used (ie, REDUCE-IT criteria, US Food and Drug Administration label, Health Canada label, practice guidelines) and the population studied. Overall, eight cost-effectiveness studies across the United States, Canada, Germany, Israel, and Australia were included in this review and findings indicated that IPE is particularly cost effective in patients with established CVD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据